Brennan has a successful, 25 year track record of driving growth and commercializing transformative therapies in med-tech. He most recently served as Chief Commercial Officer for Surgical Specialties Corp, where significant improvements in top and bottom line performance led to acquisition by Vivo Capital in 2017. Prior, he was VP & GM of Covidien’s $650M Endovascular business and VP, Sales and Marketing for their $1B+ Peripheral Vascular sector. In his tenure, these franchises rapidly transformed into a market leading brand through multiple product introductions, disruptive technology acquisitions, and market development campaigns. Before Covidien, he spent 12 years at Medtronic where he was VP, US Sales and Director, Global Marketing for their aortic stent graft business, where he helped develop these therapies into what is now the standard of care in a $2 billion global market.